Wave Life Sciences Ltd. (WVE) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "WVE"
      ],
      "issuer_cik": "0001631574",
      "owner_cik": "0001555851",
      "accession_number": "0001193125-26-349962",
      "form_type": "4",
      "filing_date": "2026-08-13",
      "period_of_report": "2026-08-12",
      "issuer_name": "Wave Life Sciences, Inc.",
      "issuer_trading_symbol": "WVE",
      "owner_name": "Rawcliffe Adrian",
      "is_director": true,
      "is_officer": false,
      "is_ten_percent_owner": false,
      "is_other": false,
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-08-12",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 12700,
      "transaction_price_per_share": 5.29,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 0,
      "transaction_value": 67183,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026."
        },
        {
          "id": "F2",
          "description": "The price reflected is the weighted-average sale price for stock sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $5.16 to $5.42 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."
        }
      ],
      "remarks": "On August 7, 2026, Wave Life Sciences, Inc., a Delaware corporation, became the successor of Wave Life Sciences Ltd., a company organized under the laws of the Republic of Singapore (\"Wave-Singapore\"), pursuant to a scheme of arrangement under Singapore law under which all issued ordinary shares in the capital of Wave-Singapore were exchanged on a one-for-one basis for shares of common stock of Wave Life Sciences, Inc. (the \"Redomiciliation\"). The Redomiciliation had the effect of changing Wave-Singapore's domicile, but did not alter the proportionate interests of securityholders.\n\nExhibit 24.1 - Power of Attorney"
    },
    {
      "tickers": [
        "WVE"
      ],
      "issuer_cik": "0001631574",
      "owner_cik": "0001655029",
      "accession_number": "0001193125-26-349963",
      "form_type": "4",
      "filing_date": "2026-08-13",
      "period_of_report": "2026-08-11",
      "issuer_name": "Wave Life Sciences, Inc.",
      "issuer_trading_symbol": "WVE",
      "owner_name": "Wagner Heidi L",
      "is_director": true,
      "is_officer": false,
      "is_ten_percent_owner": false,
      "is_other": false,
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-08-11",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 7000,
      "transaction_price_per_share": 6.01,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 44930,
      "transaction_value": 42070,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026."
        }
      ],
      "remarks": "On August 7, 2026, Wave Life Sciences, Inc., a Delaware corporation, became the successor of Wave Life Sciences Ltd., a company organized under the laws of the Republic of Singapore (\"Wave-Singapore\"), pursuant to a scheme of arrangement under Singapore law under which all issued ordinary shares in the capital of Wave-Singapore were exchanged on a one-for-one basis for shares of common stock of Wave Life Sciences, Inc. (the \"Redomiciliation\"). The Redomiciliation had the effect of changing Wave-Singapore's domicile, but did not alter the proportionate interests of securityholders.\n\nExhibit 24.1 - Power of Attorney"
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.